U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257640) titled 'IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia' on Nov. 20.
Brief Summary: This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Hematologic Diseases
Neoplasms
Intervention:
DRUG: IL-5 CAR-T cells
Each subject receive IL-5 CAR T-cells by intravenous infusion
Recruitment Status: RECRUITING
Sponsor: Zhejiang University
Information provided by (Responsible Party): He Huang, Zhejiang University
Disclaimer...